Janux Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $125.9M | $68.4M | $54.9M | $53.4M | $26.2M | $3.0M |
| SG&A Expense | — | $41.8M | $41.0M | $26.1M | $22.3M | $10.3M | $1.8M |
| Operating Income | — | $-157.7M | $-98.8M | $-73.0M | $-67.1M | $-32.9M | $-4.8M |
| Operating Margin | — | -1,576.7% | -933.6% | -902.9% | -779.0% | -905.4% | — |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | — | — | — |
| Net Income | — | $-113.6M | $-69.0M | $-58.3M | $-63.1M | $-32.7M | $-6.8M |
| Net Margin | — | -1,136.3% | -651.6% | -721.2% | -732.2% | -898.3% | — |
| EPS (Basic) | — | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | $-0.07 |
| EPS (Diluted) | — | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | $-0.07 |
| Shares Outstanding (Basic) | 60.8M | 62.0M | 53.8M | 44.0M | 41.5M | 23.5M | 23.6M |
| Shares Outstanding (Diluted) | 60.8M | 62.0M | 53.8M | 44.0M | 41.5M | 23.5M | 23.6M |
| Dividends Per Share | — | — | — | — | — | — | — |